What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Jacques Cadranel mainly investigates Internal medicine, Pathology, Surgery, Lung cancer and Gastroenterology.
His Internal medicine research is multidisciplinary, relying on both Aspergillosis, Immunology and Oncology.
Jacques Cadranel has included themes like Docetaxel and Bioinformatics in his Oncology study.
The study incorporates disciplines such as Dermatology, Pleural effusion, Lung and Tumor-infiltrating lymphocytes in addition to Pathology.
His studies in Surgery integrate themes in fields like Adverse effect, Incidence, Cohort and Pneumonia.
His work carried out in the field of Lung cancer brings together such families of science as Cancer, Anal cancer, Adenocarcinoma, Carcinoma and Risk factor.
His most cited work include:
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (730 citations)
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures (552 citations)
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) (478 citations)
What are the main themes of his work throughout his whole career to date?
Jacques Cadranel mostly deals with Internal medicine, Oncology, Lung cancer, Pathology and Lung.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery.
His research integrates issues of KRAS and Epidermal growth factor receptor in his study of Oncology.
His Lung cancer research includes themes of Cancer, Performance status and Cancer research.
In his research on the topic of Pathology, Immunology is strongly related with Bronchoalveolar lavage.
His specific area of interest is Lung, where Jacques Cadranel studies Respiratory disease.
He most often published in these fields:
- Internal medicine (48.30%)
- Oncology (25.95%)
- Lung cancer (23.67%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (48.30%)
- Oncology (25.95%)
- Lung cancer (23.67%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Non small cell and Cancer research.
His research related to Cancer, Idiopathic pulmonary fibrosis, Chemotherapy, Lung and Cohort might be considered part of Internal medicine.
The concepts of his Oncology study are interwoven with issues in Confidence interval, Hazard ratio, Treatment outcome and KRAS.
His Lung cancer research is multidisciplinary, incorporating elements of Prospective cohort study, Performance status and Adenocarcinoma.
The various areas that Jacques Cadranel examines in his Non small cell study include Molecular biology, Response Duration and Immunotherapy.
His work focuses on many connections between Cancer research and other disciplines, such as Afatinib, that overlap with his field of interest in Treatment options and ErbB.
Between 2018 and 2021, his most popular works were:
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. (181 citations)
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial (140 citations)
- Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer (28 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Internal medicine, Oncology, Cancer, Lung cancer and Non small cell are his primary areas of study.
His work in Cohort study, Chemotherapy, Cohort, Mortality rate and Intensive care unit are all subfields of Internal medicine research.
His biological study spans a wide range of topics, including Mucinous Adenocarcinomas, Lung and Treatment outcome.
Jacques Cadranel combines subjects such as Fusion gene, Disease and Retrospective cohort study with his study of Cancer.
His work in the fields of Osimertinib overlaps with other areas such as In patient.
His Non small cell research integrates issues from Treatment of lung cancer, Therapeutic algorithm, Confidence interval and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
